
✓
Open
24 Mar 2026
✓
Close
27 Mar 2026
3
Allotment
—
✓
Listing
Thu, Apr 2, 2026
Price Band
₹372 to ₹392
Issue Size
1,04,28,288 shares (agg. up to ₹409 Cr)
Lot Size
38 Shares
Listing Date
Thu, Apr 2, 2026
Latest GMP
₹0
Est. Gain
0%
✦ AI Insight
GMP Trend
02-04-2026₹0Est. ₹392+0%
01-04-2026₹0Est. ₹392+0%
31-03-2026₹0Est. ₹392+0%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 1.08x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| NET Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,064.90 (+0.13%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,419.00 (-3.11%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹165.27 (-1.98%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.18 (+0.53%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹178.60 (+0.17%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹262.00 (-0.70%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹242.70 (-0.98%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹105.05 (+2.79%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹249.35 (+2.66%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹73.50 (-2.00%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹290.00 (-0.60%) |
| Astonea Labs Ltd. | SME | ₹37.67 Cr | ₹135 | 27.36 | ₹135.65 | +0.48% | ₹283.00 (-1.57%) |
| Accretion Pharmaceuticals Ltd. | SME | ₹29.75 Cr | ₹101 | 21.29 | ₹82.95 | -17.87% | ₹166.00 (+3.33%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capacity expansion and upgradation of manufacturing facilities | 110.80 |
| 2 | Establishment of a new R&D Centre; | 18.02 |
| 3 | Repayment / prepayment of certain outstanding borrowings | 14.30 |
| 4 | Working capital requirements | 33.00 |
| 5 | Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | 35.64 |
| 6 | General corporate purposes | 44.74 |
| 7 | Issue Expenses | 40.84 |
| Total | 297.34 |
About Sai Parenteral's IPO
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets. The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa. The company owns and operates five manufacturing facilities in India. Four are lo
Contact Details
Sai Parenteral's Ltd. AddressPlot No 395th floor, Lavanya Arcade Jayabheri EnclaveGachibowli, K.V.Rangareddy, Seri LingampallyHyderabad, Telangana, 500032+91 79979 91301cs@saiparenterals.comVisit Website